Everyone is watching AI.
Fewer people are noticing where some of that money may be going next.
Biotech quietly spent the last few years getting crushed after the pandemic boom faded. Many companies lost 50% to 90% of their value, capital dried up, and investors largely stopped paying attention.
Now the mood feels different.
Money is slowly flowing back into the sector.
And AI is giving investors a brand-new reason to look again.
Drug discovery that once took years can now be accelerated with AI models. Genomics, protein design, personalized medicine, and clinical trial analysis suddenly have a much stronger investment story than they did just a few years ago.
That’s changing the conversation.
It also reminds me of another market cycle.
After the dot-com bubble burst, biotech became one of the market’s biggest growth stories during the early 2000s. It wasn’t just one company. The entire sector attracted capital because investors believed a new wave of innovation had arrived.
I’m not saying history repeats exactly.
But the setup looks familiar.
A beaten-down sector.
Improving sentiment.
A powerful new technology acting as a catalyst.
The biggest mistake investors make is assuming the next bull market always comes from the same winners.
Sometimes the next leadership group is the one almost nobody wanted to own a year earlier.
Biotech may not replace AI.
But AI could end up being the reason biotech has its next big run.
Disclaimer: Not financial advice